Skip to Main Content
Contribute Try STAT+ Today

SAN FRANCISCO — For companies that monitor and coach patients with chronic disease, there are few things more valuable than data on how those patients are faring at any given moment. Now, one of those companies, Livongo (LVGO), is about to have vastly more information on thousands of its members with diabetes.

Livongo announced Monday that it will integrate a continuous glucose monitor made by Dexcom (DXCM), the big manufacturer in the space, into its system. That blockbuster device, called the G6 CGM system, reads a diabetes patient’s blood glucose level every five minutes — offering 288 data points a day that Livongo can mine for insights to try to help patients manage their disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.